Catalyst Funds Management Pty LTD Astria Therapeutics, Inc. Transaction History
Catalyst Funds Management Pty LTD
- $455 Billion
- Q3 2024
A detailed history of Catalyst Funds Management Pty LTD transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 3,700 shares of ATXS stock, worth $38,924. This represents 0.01% of its overall portfolio holdings.
Number of Shares
3,700Holding current value
$38,924% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ATXS
# of Institutions
108Shares Held
49.1MCall Options Held
27.6KPut Options Held
29.7K-
Perceptive Advisors LLC New York, NY6.49MShares$68.2 Million1.87% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$53.7 Million0.78% of portfolio
-
Vestal Point Capital, LP New York, NY4MShares$42.1 Million3.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$37.4 Million6.36% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$37 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $160M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...